Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib and Toripalimab in Advanced Hepatocellular Carcinoma
NCT04368078Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2020
- Primary completion
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, lenvatinib in hepatocellular carcinoma (HCC), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
toripalimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04368078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04368078.